Redeye retains its positive view of Proact following a solid Q4 report with EBITA matching our forec...
Redeye maintains its positive view of Transtema following a Q4 showing a better q/q margin improveme...
Q4: sales SEK 25m,-16% y-o-y; EBIT margin of -1.9% (17.
Redeye adjusts its base case in light of the recent right issue.
Etteplan's Q4 results were as expected, following the preliminary numbers released with January's pr...
Redeye updates its view of IRLAB following the Q4 report and largely reiterate our previous view.
Ökad transparens Som förväntat fick vi se rörelsekostnaderna krypa uppåt igen i det fjärde kvartalet...
Fjärde Kvartalet Omsättningen var +4% y/y, 271 mkr (261), varav 3% organisk och 1% valuta.
Redeye sees a positive Q4 report, with the significant q/q margin improvement being the highlight.
- Sales +15% y-o-y, +13% vs. ABGSCe - Underlying operating profit well above ABGSCe - Expect cons to...
Redeye comments on I-Tech’s Q4 figures figures missing our expectations across the board.
- Adj. EBIT -21% vs ABGSC, -21% vs FactSet consensus - Consensus to cut EBIT by 5% - Staff reduction...
- Sales -23% and adj. EBIT SEK -7m vs. consensus - Elevated temp.
Redeye comments on Sleep Cycle's Q4 2023 report, which continued to show a q/q growth rate in the su...
Finnair reports Q4 on Feb 14. In our view this year’s summer season will again lift earnings as volu...
CapMan’s Q4 results were below expectations, with revenue of EUR 14.
Redeye states sales and adjusted EBITDA were better-than-expected and Sivers achieved its adjusted E...
Redeye comments on the Q4 report released earlier this morning.
Redeye updates Spago Nanomedical after reporting the Q4 result.
Marimekko reports its Q4 results on 15th of February.
